Short answer
Arcus Biosciences, Inc. (RCUS) filed its fiscal 2025 10-K annual report with the SEC on Feb 25, 2026. It reported revenue of $33M (−35.3% year over year) and net income of −$353M.
- Top risk flagged: Regulatory risk from Gilead collaboration amendment causing revenue catch-up of $143M in 2025, impacting timing and recognition of license income
FY2025 key financial metrics · XBRL
- Revenue
- $33M
- −35.3% YoY
- Net income
- −$353M
- −24.7% YoY
- Operating margin
- -1169.7%
- −522.6 pp YoY
- EPS (diluted)
- −$3.29
- −4.8% YoY
- ROE
- -55.9%
- +2.4 pp YoY
- Operating cash flow
- −$482M
- −183.5% YoY
Source: XBRL data from the Arcus Biosciences, Inc. (RCUS) FY2025 10-K on SEC EDGAR. USD.
Arcus Biosciences, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: Development and commercialization of investigational pharmaceutical products in immuno-oncology
- No new products or segments introduced; increased emphasis on regulatory, pricing, and healthcare reform risks in U.S. markets
- Strategic risk focus shifted toward navigating U.S. drug pricing reforms and increased government healthcare cost containment measures
- Significant stock ownership concentration with Gilead owning 25.1% and management owning 39.5% collectively as of December 31, 2025
- Implementation of exclusive Delaware Court of Chancery forum for stockholder disputes to limit litigation venue options
Management Discussion & Analysis
- No product sales revenue; all revenue from license, collaboration, and development services agreements
- License and development services revenue recognized based on percentage completion of R&D obligations
- R&D expenses include clinical, payroll, supplies, consulting, contract research; expect near-term R&D decrease due to winding down domvanalimab studies
- Cash, cash equivalents, and marketable securities totaled $1.0 billion as of Dec 31, 2025, sufficient to fund operations until at least H2 2028
- Management highlights risks and uncertainties; key focus on advancing casdatifan and inflammation programs with potential increased late-stage investment
Risk Factors
- Regulatory risk from Gilead collaboration amendment causing revenue catch-up of $143M in 2025, impacting timing and recognition of license income
- Macroeconomic exposure to collaboration funding variability, e.g., Taiho option revenue dropped from $15M in 2024 to $7M in 2025
- Operational risk of impairment on right-of-use office assets due to 2024 updated space plans, reflecting changing facility requirements
- Market disruption risk from Gilead's voluntary return of etrumadenant license, affecting Arcus's revenue and pipeline strategy
- Financial risk from non-cash interest expenses related to liabilities under BVF royalty sale, impacting net income volatility
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.